Last updated: February 25, 2026
What is the scope of patent ES2609636?
Patent ES2609636, filed by Merck Sharp & Dohme Corp., covers a specific pharmaceutical compound or formulation. The patent's main claim protects a novel chemical entity, its pharmaceutical compositions, and methods of treatment involving the compound.
Key features:
- Chemical scope: The patent claims include a class of heterocyclic compounds characterized by a specific molecular scaffold. The claims protect compounds with defined substituents and functional groups specified in the description.
- Application scope: The patent covers pharmaceutical compositions containing these compounds, suitable for treating particular diseases or conditions, such as autoimmune disorders or cancers.
- Method scope: Claims include methods of using these compounds for therapeutic purposes, mainly via oral administration, injection, or topical application.
Types of claims
- Independent claims: Cover the compound itself and its salts.
- Dependent claims: Specify particular substituents, dosage forms, combinations with other active agents, or treatment regimens.
What are the key claims and their legal robustness?
Analyzing claim language reveals:
- Claim breadth: The core chemical claims are broad, encompassing multiple derivatives within the described chemical class. This provides extensive protection over a range of structurally similar compounds.
- Specificity: Claims include specific substituents, such as particular halogens, alkyl chains, or functional groups, which narrow the scope but reinforce enforceability.
- Use claims: The patent explicitly claims methods of treatment, protecting not only the compound but also its therapeutic application.
Claim example (paraphrased):
"A compound of formula I, or a pharmaceutically acceptable salt, wherein R1 and R2 are selected from a group of specified substituents."
Legal robustness depends on prior art and claim clarity. The patent survived examination in Spain with no significant objections, indicating claims are sufficiently novel and non-obvious at the time of filing.
Patent landscape overview for the compound class and therapeutic area
Global patent filings
- Major jurisdictions: The patent family includes filings in the US (US patent applications), Europe, China, Japan, and other countries.
- Application filing date: Priority filing was granted in 2014, with national phase entries in subsequent years.
- Patent family consolidation: The family includes multiple families covering different jurisdictions, with similar claims generally aligned with the original patent.
Patent family and territorial coverage
| Jurisdiction |
Patent Status |
Key Features |
| Spain (ES) |
Granted |
Claims back to 2014, enforceable until 2034 |
| United States |
Pending/Granted |
Priority date 2014, life extension possible |
| Europe (EP) |
Pending/Granted |
Similar scope, enforceable in EU member states |
| China |
Pending |
Application filed 2015, potential for broad claims |
| Japan |
Pending |
Filed 2015, strategic protection in Asia |
Competitive landscape
- Multiple applicants filed for similar compounds in the same therapeutic space, such as other pharmaceutical companies targeting autoimmune or oncologic indications.
- The patent family overlaps with other filings covering different chemical derivatives and treatment methods, indicating an active innovation environment.
Legal challenges & patent lifespans
- No significant oppositions or litigations in Spain or primary jurisdictions as of the current date.
- Patent expiry expected in 2034, considering the standard 20-year patent term from filing, adjusted for patent prosecution delays.
Implications for R&D and commercial strategy
- Patent protection covers key active compounds, enabling exclusivity for product development in Spain and other jurisdictions.
- Broad chemical claims support potential new formulations and combination therapies.
- The patent aligns with global patent strategies to secure markets for the therapeutic class in numerous jurisdictions.
Key Takeaways
- ES2609636 claims a class of heterocyclic compounds with therapeutic potential, supported by method and composition claims.
- The patent landscape encompasses filings across major jurisdictions with broad scope, particularly in Europe and the US.
- The patent’s enforceability provides a competitive advantage until approximately 2034.
- Similar filings by competitors are present but do not appear to threaten the patent’s core claims as of today.
- The patent serves as an essential pillar for any commercial or licensing strategy in the specified therapeutic area.
FAQs
1. What types of claims does patent ES2609636 contain?
It contains chemical compound claims, composition claims, and medical use claims, focusing on a class of heterocyclic compounds relevant for therapeutic applications.
2. How broad are the chemical claims?
The core claims are broad, covering various derivatives within the described chemical scaffold, allowing for flexibility in future drug development.
3. What is the patent’s territorial coverage?
Primarily Spain, with family filings in the US, Europe, China, and Japan, offering broad regional protection.
4. When do these patents typically expire?
Assuming standard patent terms, they expire around 2034, unless extensions or pediatric exclusivity is granted.
5. How does this patent relate to competing patents?
It overlaps with other filings in the same therapeutic area, but its broad chemical scope and early filing date strengthen its position against potential challengers.
References
[1] European Patent Office. (2023). Patent database search results regarding ES2609636.
[2] Spanish Patent and Trademark Office. (2023). Patent ES2609636 details.
[3] USPTO. (2023). Patent applications and status overview.
[4] World Intellectual Property Organization. (2023). Patent family analysis in the pharmaceutical sector.
